TaiRx, Inc. (TPEX:6580)

Taiwan · Delayed Price · Currency is TWD

15.00

-1.00 (-6.25%)

Sep 15, 2026, 1:58 PM CST

Market Cap	832.08M -75.0%
Revenue (ttm)	29.44M +90.4%
Net Income	-231.99M
EPS	-2.09
Shares Out	56.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	306,433
Open	16.25
Previous Close	16.00
Day's Range	14.35 - 16.25
52-Week Range	11.95 - 31.80
Beta	0.37
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2026

About TaiRx

TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic dev... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2011

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 6580

Full Company Profile

Financial Performance

In 2025, TaiRx's revenue was 27.88 million, an increase of 239.03% compared to the previous year's 8.22 million. Losses were -221.13 million, 59.3% more than in 2024.

Financial Statements